Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 5623

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 9

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Diagnostic Substances
  • Cancer
  • Disease
  • Pharmaceuticals
  • Medical
  • Veterinary

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5623

License Grant
The Licensor hereby grants to Licensee and its Affiliates an exclusive license without the right to grant sublicenses in the Territory to the Licensed Intellectual Property to: (a) confirm performance of the Cathepsin K ELISA Test and (b) use the Cathepsin K ELISA Test to offer and provide services within the cDx Field and the rDx Field.  The Licensee shall have the right to use the Trademarks.
License Property
The Licensor has developed a blood test known as the Cathepsin K ELISA Test to detect and quantify the Cathepsin K protein inserum, and holds rights to certain intellectual property in and to the Cathepsin K ELISA Test.  Cathepsin K, abbreviated CTSK, is an enzyme which in humans is encoded by the CTSK gene.

Cathepsin K is a lysosomal cysteine protease involved in bone remodeling and reabsorption. This protein, which is a member of the peptidase C1 protein family, is predominantly expressed in osteoclasts.

Field of Use
CDX Field means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

RDX Field means use in vitro diagnostic testing services in Clinical Trials.

IPSCIO Record ID: 5622

License Grant
The Licensor hereby grants an exclusive license without the right to grant sublicenses in the Territory to the Licensed Intellectual Property to: (a) confirm performance of the Colon 101 ELISA Test and (b) use the Colon 101 ELISA Test to offer and provide services within the cDx Field and the rDx Field.

Licensee and its Affiliates shall have the right to use the Trademarks, solely in connection with the use of the Colon 101 ELISA Test.

CDX field means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

RDX Field means use in vitro diagnostic testing services in Clinical Trials.

The Licensee shall have the right to use the Trademarks.

License Property
The Licensor has developed a blood test known as the Colon 101 ELISA Test  to detect and quantify the Colon 101 protein in serum.
Field of Use
'CDX Field' means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

'RDX Field' means use in in vitro diagnostic testing services in Clinical Trials.

IPSCIO Record ID: 29096

License Grant
The Licensor,not-for-profit corporation, grants a non-exclusive subLicenses to such patents to the Licensee in the field of commercial diagnostic testing services for detection of UGT1A1 in humans effective April 14, 2006. The Licensee will pay an upfront fee and royalties.

The Licensor Licensed certain patents related to UGT1A1, from a University pursuant to a License Agreement dated November 18, 2005.

License Property
UGT1A1 is a hepatic enzyme primarily responsible for conjugation of bilirubin. UGT1A1 also catalyzes the glucuronidation of SN-38, the active metabolite of irinotecan and the main source of treatment-related toxicity.

US Issued Pat App No. 08/423,641, filing date 04/17/95, Patent No. 5,786,344
US Issued Pat App No. 09/251,274, filing date 02/16/99, Patent No. 6,395,481
US Issued Pat App No. 10/061,693, filing date 02/01/02, Patent No. 6,472,157

Field of Use
Field means commercial diagnostic testing services for detection of UGT1A1 in humans. Field does not include the research, development, manufacture, marketing, or sale of therapeutic products. Commercial diagnostic testing services shall include, but not be limited to, in-house laboratory tests pursuant to CLIA, clinical trials testing, and the manufacture, use and sale of diagnostic kits.

IPSCIO Record ID: 6493

License Grant
The Licensee signed the Assignment and Consultation Agreement with a Doctor, with whom the Licensee has collaborated with on the appendicitis products. The Licensee expects that expenditures will be incurred to continue to advance the initial appendicitis blood test technology, AppyScoreâ„¢ through the FDA application and clearance process in addition to advancing development of the next generation appendicitis products.
Field of Use
AppyScore Human Appendicitis Triage Blood Test: Licensee progresses in the development and testing of its first-generation blood-based human diagnostic tests designed to rapidly aid in the diagnosis of appendicitis in patients complaining of abdominal pain. Specifically, we have created and optimized a specialized test to detect a marker in the blood associated with appendicitis and have tested this assay in several clinical research trials involving hundreds of human patients.   The  appendicitis triage blood screen test: AppyScore,  is based on a blood test result scoring system designed to be used as an initial appendicitis triage or screening test for patients entering an emergency department or urgent care facility complaining of abdominal pain.

IPSCIO Record ID: 605

License Grant
Swiss Licensor grants to Licensee and its Affiliates, a non-exclusive worldwide right and license under the Licensed Patents as follows: to perform in vitro human and/or animal diagnostic testing procedures on a sample of material obtained from a human or animal, as applicable, solely to detect the presence, absence or quantity of a nucleic acid sequence associated with a disease or condition in the Licensed Fields.
License Property
Other Technology shall mean the processes covered by the method claims (if they are Valid Claims) of United States Patent Nos. 5,008,182, 5,677,152, 5,773,258 and 5,176,995, and any reissue or reexamination patents thereof, and the claims (if they are Valid Claims) of United States Patent No. 5,110, 920, and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

PCR Technology shall mean polymerase chain reaction technology covered by Valid Claims of United States Patent Nos. B1 4,683,195, B1 4,683,202, and 4,965,188 and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

Quantitation Technology shall mean the method claims (if they are Valid Claims) of United States Patent Nos. 5,389,512 and 5,219,727, and any reissue or reexamination patents thereof, and claims 1-4, 8, 9 and 15-18 (if they are Valid Claims) of United States Patent No. 5, 476,774, and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

RT and RT-PCR  Technology shall mean the reverse transcription process covered by the method claims (if they are Valid Claims) of United States Patent Nos. 5,407,800, 5,310,652, 5,561,058, 5,618,703 and 5,322,770, and any reissue or reexamination patents thereof, and the claims (if they are Valid Claims) of United States Patent No. 5,693,517, and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

'5' Nuclease Technology' shall mean only the processes defined by the method claims (if they are Valid Claims) of United States Patent Nos. 5,210,015 and 5,487,972 and any reissue or reexamination patents thereof and the reaction mixture claims (if they are Valid Claims) of United States Patent No. 5,804,375 and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

Field of Use
Diagnostic Services Field means the field of human in vitro diagnostics for the detection, quantitation, monitoring, genotyping, or phenotyping, of genetic and infectious diseases, disease susceptibility, genetic pre-disposition to disease or cancer; analyzing specimens taken from a human being for the purpose of testing, with respect to that human being, for a physiological or pathological state, for a congenital abnormality, for safety and compatibility of a treatment or to monitor therapeutic measures; or any use of PCR as a testing service to provide to a person data, results or interpretations of any application of PCR for purposes of therapy or diagnosis of a human being, including, without limitation, clinical laboratory services, whether or not a fee is charged for such services; tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation; Parentage Determination; diagnosis, disease management; and clinical trials, whether or not a patient result is provided directly or indirectly to a patient.  Licensed Field shall specifically exclude any services performed for screening of blood and/or blood products.

IPSCIO Record ID: 7173

License Grant
The Licensor grants to the Licensee, a non-exclusive, royalty-bearing SubLicense in the territory in the Field of laboratory testing services and products, including without limitation, diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow or blood cells. The Field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.
License Property
Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, including Canadian Patent Application 2585965 as well as all continuations, divisions, reissues, re-examinations, renewals, or extensions of such patents subject to the rights granted by Original Licensor to the Licensor pursuant to the Exclusive License Agreement, as limited by this Agreement.
Field of Use
The field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.

IPSCIO Record ID: 5202

License Grant
The University granted the Licensee an exclusive right and license to utilize the Licensed Technology to develop the Licensed Products.
License Property
The patented technology refers Thymidine Kinase Isoenzyme Diagnostics and Thymidine Kinase Hybridomas. Thymidine Kinase – 1 or TK1 is a cancer screening technology.  A kit using the ELISA format, would require only a small blood sample and could also be incorporated into a standard blood test panel. The ELISA format is a fundamental tool of clinical immunology, based on the principle of antibody-antibody interaction.   A kit using this format provides easy visualization of results, detecting the presence and amount of TK1, and can be completed without the expense and other problems of using radioactive materials.

Thymidine kinase is an enzyme, a phosphotransferase (a kinase): 2'-deoxythymidine kinase, ATP-thymidine 5'-phosphotransferase, EC 2.7.1.21.[2][3] It can be found in most living cells. It is present in two forms in mammalian cells, TK1 and TK2. Certain viruses also have genetic information for expression of viral thymidine kinases.

Field of Use
The Licensee shall develop a serum Enzyme-Linked Immunosorbent Assay (ELISA) diagnostic kit for the detection of Thymidine Kinase-1 Isoenzyme.

IPSCIO Record ID: 891

License Grant
The Licensor hereby grants Licensee a non-exclusive sublicense, without the right to sublicense others, under the Licensed Patents to make, have made, use, import, have sold, offer to sell and sell Licensed Products within the Field and within the territory.
License Property
UGT1A1 or uridine diphosphate glucuronosyltransferaseisoform 1A1, test, which is designed to help determine the initial dosing of irinotecan, a leading drug for a broad variety of cancers.

The UGT1A1 gene is part of a complex that encodes several UDP-glucuronosyltransferases.

Patents
    Domain    Status    Pat App No    Filing Date    Patent No
    US    Issued    08/423,641    04/17/95    5,786,344
    US    Issued    09/251,274    02/16/99    6,395,481
    US    Issued    10/061,693    02/01/02    6,472,157

Field of Use
Field means commercial diagnostic testing services for detection of UGT1A1 in humans. Field does not include the research, development, manufacture, marketing, or sale of therapeutic products. Commercial diagnostic testing services shall include, but not be limited to, in-house laboratory tests pursuant to CLIA, clinical trials testing, and the manufacture, use and sale of diagnostic kits.

IPSCIO Record ID: 7117

License Grant
The Sub-Licensor is the exclusive licensee of the Patent Rights relating to the Field under the Exclusive License Agreement dated May 2006, and is willing to grant to the Sub-Licensee a non-exclusive, royalty-bearing Sublicense in the Territory to use such Patent Rights in the Field.
License Property
The Sub-Licensee shall have no right to further sublicense.

Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, including Canadian Patent Application 2585965 as well as all continuations, divisions, reissues, reexaminations, renewals, or extensions of such patents subject to the rights granted by Original Licensor pursuant to the Exclusive License Agreement, as limited by this Agreement.

Field of Use
Field shall mean identification and diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow, blood cells, and other cellular specimens. Specifically excluded is testing of urine or any other cell free specimen. The Field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.